BioCentury
ARTICLE | Clinical News

Tasimelteon: Phase IIb/III started

November 14, 2011 8:00 AM UTC

Vanda disclosed in its 3Q11 earnings that in September it began the double-blind, placebo-controlled, U.S. Phase IIb/III MAGELLAN trial to evaluate once-daily 20 mg tasimelteon for 8 weeks in about 50...